Orris

Write a Long answer questions on Molecular basis of carcinogenesis fro Robbins book for 20 marks for MD pathology final exam

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the comprehensive content I need from Robbins. Let me now compose the full long-answer exam question.

MOLECULAR BASIS OF CARCINOGENESIS

Long Answer Question - 20 Marks (MD Pathology Final Examination)

(Based on Robbins & Cotran Pathologic Basis of Disease, 10th Edition, Chapter 7)

INTRODUCTION

Cancer is a genetic disease at the cellular level but is fundamentally a disease of disordered growth regulation resulting from the sequential accumulation of somatic mutations and epigenetic alterations. The molecular basis of carcinogenesis can be organized around the concept of the Hallmarks of Cancer - eight fundamental biologic capabilities that all cancers must acquire to become fully malignant:
  1. Self-sufficiency in growth signals (oncogene activation)
  2. Insensitivity to growth-inhibitory signals (tumor suppressor gene inactivation)
  3. Altered cellular metabolism (Warburg effect)
  4. Evasion of apoptosis
  5. Limitless replicative potential (immortality)
  6. Sustained angiogenesis
  7. Ability to invade and metastasize
  8. Ability to evade the host immune response
These are enabled by genomic instability and tumor-promoting inflammation.

I. SELF-SUFFICIENCY IN GROWTH SIGNALS: ONCOGENES

Proto-oncogenes and Oncogenes

Proto-oncogenes are normal cellular genes encoding proteins that promote cell growth and proliferation. When mutated or dysregulated, they become oncogenes that encode constitutively active oncoproteins - proteins that drive cell growth even in the absence of external stimuli.
The normal signaling cascade from growth factor binding to cell division involves:
  1. Growth factor binding to its specific receptor
  2. Transient activation of the receptor, which activates cytoplasmic signal transducers
  3. Transmission of signals via effector proteins and second messengers
  4. Induction of transcription factors and epigenetic alterations
  5. Expression of genes promoting cell cycle entry and division

A. Growth Factors

Some cancer cells synthesize the same growth factor to which they are responsive, creating an autocrine loop. Example: gliomas overexpress both PDGF and PDGFR; sarcomas overexpress TGF-α and EGFR.

B. Growth Factor Receptors (Receptor Tyrosine Kinases)

Growth factor receptors, particularly receptor tyrosine kinases (RTKs), are among the most important oncoproteins. Constitutive RTK activation occurs by:
  • Point mutations (e.g., EGFR mutations in non-small cell lung cancer)
  • Gene amplification (e.g., ERBB2/HER2 amplification in ~20% of breast cancers)
  • Chromosomal rearrangements creating fusion oncoproteins (e.g., BCR-ABL in CML)
  • Overexpression without structural alteration
The RET proto-oncogene encodes a tyrosine kinase receptor; point mutations cause multiple endocrine neoplasia (MEN) type 2A and 2B, and rearrangements creating RET fusion oncogenes occur in papillary carcinomas of the thyroid.

C. Signal Transducers: The RAS Oncoproteins

RAS is the most commonly mutated oncogene in human tumors, mutated in ~30% of all cancers (highest frequencies in pancreatic carcinoma ~90%, colon carcinomas ~50%, lung adenocarcinomas ~30%). RAS proteins are membrane-associated G proteins that cycle between active GTP-bound and inactive GDP-bound states. Point mutations in RAS (commonly at codons 12, 13, or 61) impair its intrinsic GTPase activity, locking it in the active GTP-bound state, leading to constitutive activation of downstream pathways including:
  • RAF/MEK/ERK (MAPK pathway) - proliferation
  • PI3K/AKT/mTOR pathway - cell survival and metabolism
BRAF is mutated in ~60% of melanomas and is an important therapeutic target.

D. Transcription Factor Oncoproteins: MYC

MYC is a transcription factor that controls the expression of many genes involved in cell growth. It is activated by mitogenic signals (Wnt, RAS) and is amplified or overexpressed in many tumors. MYC is mutated in Burkitt lymphoma through t(8;14) translocation juxtaposing c-MYC with the immunoglobulin heavy chain locus. NMYC is amplified in 25-30% of neuroblastomas and portends a poor prognosis. MYC stimulates cell cycle entry, promotes Warburg metabolism, and enhances VEGF production.

E. Mechanisms of Oncogene Activation

MechanismExample
Point mutationRAS mutations in pancreatic cancer
Gene amplificationERBB2 (HER2) in breast cancer; NMYC in neuroblastoma
Chromosomal translocationBCR-ABL in CML; MYC in Burkitt lymphoma; PML-RARA in APL
Insertional mutagenesisRetroviral insertion near proto-oncogene
Double minutes (extrachromosomal circular DNA fragments) and homogeneous staining regions on chromosomes are the two microscopically visible hallmarks of gene amplification.

II. INSENSITIVITY TO GROWTH INHIBITORY SIGNALS: TUMOR SUPPRESSOR GENES

Tumor suppressor genes (TSGs) encode proteins that normally restrain cell proliferation. Their inactivation removes the "brakes" on cell division. Most TSG mutations follow Knudson's "Two-Hit Hypothesis": both alleles must be inactivated for loss of function. The first hit may be inherited (germline) or somatic; the second is always somatic.

A. RB Gene: Governor of the Cell Cycle

The RB gene (chromosome 13q14) encodes the retinoblastoma protein (pRb), the master regulator of the G1/S cell cycle checkpoint - the "restriction point."
Mechanism: In its hypophosphorylated state, pRb binds and sequesters E2F transcription factors, preventing transcription of genes needed for S-phase entry. Growth factor-driven cyclin D-CDK4/6 complexes phosphorylate pRb, causing it to release E2F, which then drives transcription of S-phase genes (cyclin E, DNA polymerase, etc.).
In cancer, pRb function is lost by:
  • Mutation/deletion of RB1 gene (retinoblastoma, osteosarcoma)
  • Overexpression of cyclin D1 or CDK4 (many cancers)
  • Mutations in CDK inhibitors, especially p16/INK4a (CDKN2A) - deleted in 75% of pancreatic carcinomas, 40-70% of glioblastomas, 50% of esophageal cancers
  • Binding and inactivation of pRb by viral oncoproteins: HPV E7, SV40 large T antigen, adenovirus E1A
Germline RB mutations: Familial retinoblastoma - children inherit one mutant allele, and somatic loss of the second allele in retinal cells causes retinoblastoma. These patients also have elevated risk of osteosarcoma and other tumors.

B. TP53 Gene: Guardian of the Genome

p53 is the most frequently mutated tumor suppressor, altered in >50% of all human cancers. It is encoded by the TP53 gene on chromosome 17p13.1. p53 is a transcription factor activated by DNA damage, hypoxia, and oncogenic stress.
Functions of p53:
  1. Cell cycle arrest: Upregulates p21/CDKN1A, which inhibits cyclin-CDK complexes, arresting cell cycle at G1/S checkpoint, allowing DNA repair
  2. Apoptosis: If damage is irreparable, p53 upregulates pro-apoptotic genes (BAX, PUMA), leading to programmed cell death
  3. Senescence: p53 can induce irreversible cell cycle arrest (senescence) in response to oncogenic stress
  4. Anti-angiogenesis: p53 stimulates thrombospondin-1 and represses VEGF expression
Under normal conditions, p53 levels are kept low by MDM2, an E3 ubiquitin ligase that promotes p53 degradation. DNA damage activates ATM/ATR kinases that phosphorylate and stabilize p53 by preventing MDM2 binding. MDM2 is amplified in ~30% of sarcomas.
Li-Fraumeni syndrome: Autosomal dominant germline TP53 mutations; patients develop sarcomas, breast cancer, brain tumors, and leukemia at young ages.
Viral inactivation of p53: HPV E6 protein binds p53 and promotes its degradation via MDM2-independent ubiquitination. This mechanism contributes to the oncogenicity of HPV in cervical carcinoma.

C. APC: Gatekeeper of Colonic Neoplasia

APC (chromosome 5q21) functions by regulating the Wnt/β-catenin signaling pathway. In resting cells, APC is part of a "destruction complex" (with Axin, GSK3β, CK1) that phosphorylates β-catenin, targeting it for proteasomal degradation. Wnt signaling blocks this complex, allowing β-catenin to translocate to the nucleus where it partners with TCF to activate genes like MYC, CCND1 (cyclin D1), and others that drive proliferation.
Loss of APC function (as in Familial Adenomatous Polyposis - FAP) leads to constitutive nuclear β-catenin accumulation and uncontrolled proliferation. FAP is caused by germline APC mutations; affected individuals develop thousands of colorectal adenomatous polyps by their teens, with nearly inevitable progression to carcinoma. Somatic APC mutations are found in 70-80% of sporadic colorectal cancers.

D. PTEN Tumor Suppressor

PTEN is a phosphatase that opposes PI3K signaling by dephosphorylating PIP3 back to PIP2, thereby inhibiting AKT activation. Loss of PTEN leads to constitutive AKT/mTOR signaling, promoting cell survival, growth, and proliferation. PTEN is among the most frequently lost tumor suppressors in human cancer (breast, prostate, endometrial cancers; glioblastoma).

E. TGF-β Pathway (SMAD Signaling)

TGF-β normally inhibits cell cycle progression by upregulating CDK inhibitors (p15, p27) and downregulating MYC. In many cancers, TGF-β signaling is bypassed by mutations in receptors (TGF-βRII, commonly mutated in microsatellite-unstable colorectal cancers) or in downstream SMAD proteins (SMAD4/DPC4 mutated in pancreatic carcinoma).

III. ALTERED CELLULAR METABOLISM: THE WARBURG EFFECT

Normal cells preferentially use oxidative phosphorylation (OXPHOS) for energy, switching to glycolysis only under hypoxic conditions. Cancer cells preferentially utilize aerobic glycolysis even in the presence of oxygen - the Warburg effect. This metabolic reprogramming:
  • Provides biosynthetic precursors (pentose phosphate pathway for nucleotides, glycolytic intermediates for amino acid and lipid synthesis)
  • Is essential for rapid cell growth
  • Is promoted by oncoproteins (RAS, MYC, mutant growth factor receptors) and opposed by tumor suppressors (PTEN, NF1, p53)
Some oncoproteins (e.g., mutant IDH1/IDH2 in gliomas and leukemias) produce "oncometabolites" such as 2-hydroxyglutarate that alter the epigenome, causing widespread changes in gene expression.

IV. EVASION OF APOPTOSIS

The intrinsic (mitochondrial) pathway of apoptosis is the main path regulated in cancer cells. It is controlled by the balance between:
  • Pro-apoptotic BCL-2 family members: BAX, BAK (pore-formers); BH3-only proteins BIM, BAD, BID, PUMA (sensitizers)
  • Anti-apoptotic BCL-2 family members: BCL-2, BCL-XL, MCL-1
When BH3 proteins overwhelm anti-apoptotic proteins, BAX/BAK form pores in the mitochondrial outer membrane, releasing cytochrome c into the cytosol. Cytochrome c binds APAF-1, activating caspase-9, which activates executioner caspase-3/7, leading to cell dismantling.
Cancer mechanisms to evade apoptosis:
  1. BCL-2 overexpression: t(14;18) translocation in follicular lymphoma juxtaposes BCL2 with the IgH locus, causing massive BCL-2 overexpression that prevents apoptosis
  2. TP53 loss: Prevents upregulation of BAX and PUMA in response to DNA damage
  3. Upregulation of IAPs (inhibitor of apoptosis proteins) that block caspase activation
  4. Activation of PI3K/AKT pathway, which phosphorylates and inactivates BAD
Therapeutic strategies targeting this pathway include venetoclax (BCL-2 inhibitor), approved for CLL and AML.

V. LIMITLESS REPLICATIVE POTENTIAL (IMMORTALITY)

Normal somatic cells have a finite replicative capacity (~60-70 divisions), after which they undergo irreversible replicative senescence driven by progressive telomere shortening. Telomeres are TTAGGG repeat sequences at chromosomal ends that shorten with each cell division. When critically short, they trigger a DNA damage response that activates p53 and p16/RB, causing senescence or apoptosis.
Cancer cells escape senescence by upregulating telomerase (TERT) - a reverse transcriptase that elongates telomeres using an RNA template. Telomerase is reactivated in >90% of human cancers but is absent from most normal somatic cells. This immortalization is essential for clonal expansion over decades.
Cancer stem cells are a subpopulation of tumor cells with self-renewing capacity that sustains tumor growth. They can arise from:
  • Transformation of normal tissue stem cells (e.g., HSCs in CML)
  • Proliferating progenitor cells that acquire "stemness" mutations (e.g., granulocyte progenitors in APL)

VI. SUSTAINED ANGIOGENESIS

Solid tumors cannot grow beyond 1-2 mm without a blood supply (the diffusion limit of oxygen and nutrients). Growing tumors must therefore induce neovascularization by tilting the angiogenic switch - the balance between pro-angiogenic and anti-angiogenic factors - toward angiogenesis.
Key pro-angiogenic signals:
  • VEGF (Vascular Endothelial Growth Factor): Main driver; induced by HIF-1α under hypoxia and by RAS, MYC, p53 loss
  • bFGF (basic Fibroblast Growth Factor): Released from ECM by proteases
  • Platelets and inflammatory cells (macrophages) contribute angiogenic factors
Anti-angiogenic factors: Thrombospondin-1 (induced by p53), angiostatin, endostatin
The clinical application of this understanding is anti-VEGF therapy (e.g., bevacizumab), which is used in colorectal cancer, renal cell carcinoma, and other tumors.

VII. INVASION AND METASTASIS

Metastasis is responsible for the majority of cancer deaths. It involves a series of sequential steps:

Steps of Metastasis (Invasion-Metastasis Cascade)

  1. Local invasion of adjacent ECM
  2. Intravasation into blood or lymphatic vessels
  3. Survival in circulation (resisting anoikis, immune attack)
  4. Arrest at distant capillary beds
  5. Extravasation into the parenchyma
  6. Colonization with formation of a micrometastasis and then macrometastasis

Epithelial-Mesenchymal Transition (EMT)

EMT is a key step in local invasion whereby carcinoma cells:
  • Lose E-cadherin (epithelial marker) - reducing cell-cell cohesion
  • Gain vimentin, N-cadherin, fibronectin (mesenchymal markers) - enhancing motility
  • Are triggered by transcription factors SNAIL, SLUG, TWIST, ZEB1/ZEB2 (often induced by TGF-β, Wnt, and Notch signals from the tumor stroma)
  • Upregulate matrix metalloproteinases (MMPs) that degrade basement membrane and ECM

Organ Tropism and Seed-Soil Hypothesis

Metastatic patterns are not random:
  • Colon cancer -> liver (portal drainage)
  • Breast cancer and prostate cancer -> bone (preferential, non-anatomical)
  • Lung cancer -> adrenals, brain
  • Neuroblastoma -> liver and bone
The seed-soil hypothesis (Paget, 1889) proposes that metastasis is favored when tumor cells ("seeds") find a compatible microenvironment ("soil") in the target organ, involving compatible adhesion molecules, chemokine receptor-ligand pairs (e.g., CXCR4/CXCL12 for breast cancer to bone marrow), and favorable stromal niches.

VIII. EVASION OF HOST IMMUNE RESPONSE

The immune system can recognize and kill tumor cells through the cancer immunoediting process (elimination → equilibrium → escape). Eventually, tumor cells that evade immunity are positively selected. Key mechanisms include:
  1. Downregulation of MHC class I molecules, reducing recognition by cytotoxic CD8+ T cells
  2. Upregulation of PD-L1 on tumor cells, which engages PD-1 on T cells and delivers an inhibitory signal, "turning off" T cells
  3. Secretion of immunosuppressive cytokines (TGF-β, IL-10, VEGF) that inhibit T cell function and promote regulatory T cells (Tregs)
  4. Loss of tumor antigens (antigen editing) eliminating recognizable neoantigens
  5. Recruitment of immunosuppressive cells: Tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), Tregs
Therapeutic implication: Checkpoint inhibitors (anti-CTLA-4 = ipilimumab; anti-PD-1 = nivolumab/pembrolizumab; anti-PD-L1 = atezolizumab) restore antitumor T cell responses. Response correlates with tumor mutational burden (TMB) - tumors with high TMB (especially mismatch repair-deficient tumors) are most likely to respond.

IX. GENOMIC INSTABILITY AS AN ENABLING CHARACTERISTIC

The acquisition of multiple driver mutations requires a "mutator phenotype" - an increased rate of mutation that accelerates cancer evolution. This results from defects in DNA repair:

A. DNA Mismatch Repair (MMR) Deficiency

MMR proteins (MSH2, MLH1, MSH6, PMS2) act as "spell checkers" during DNA replication, correcting mismatched base pairs. Loss of MMR leads to microsatellite instability (MSI) - expansion or contraction of short tandem repeat sequences throughout the genome.
  • Lynch syndrome (HNPCC): Autosomal dominant germline mutations in MSH2 or MLH1 (each ~30% of cases); predisposes to proximal colon cancer, endometrial, ovarian, and other cancers
  • Sporadic MSI cancers: Usually from epigenetic silencing of MLH1; accounts for ~15% of sporadic colorectal cancers

B. Nucleotide Excision Repair (NER) Deficiency

NER repairs UV-induced pyrimidine dimers. Inherited defects cause xeroderma pigmentosum - extreme sensitivity to sunlight and extraordinarily high risk of squamous cell carcinoma, basal cell carcinoma, and melanoma.

C. Homologous Recombination (HR) Repair Deficiency

HR repairs double-strand DNA breaks and covalent DNA cross-links.
  • BRCA1/BRCA2 mutations in ~25% of familial breast cancers (also ovarian, prostate, pancreatic cancers). These tumors are highly sensitive to PARP inhibitors (synthetic lethality)
  • Bloom syndrome (helicase mutation), ataxia-telangiectasia (ATM mutation), Fanconi anemia (>12 genes) - all show genomic instability and cancer predisposition

X. EPIGENETIC CHANGES IN CANCER

Beyond DNA mutations, carcinogenesis involves heritable epigenetic changes in gene expression without changes in DNA sequence:
  1. CpG island promoter methylation: Silences tumor suppressor genes (MLH1, CDKN2A, VHL, BRCA1) without mutation; widespread in most cancers
  2. Histone modifications: Altered acetylation and methylation of histone tails changes chromatin compaction and gene accessibility. Histone-modifying enzymes (EZH2, KDM6A) are commonly mutated in cancer
  3. Chromatin remodeling complexes: Subunits of SWI/SNF (e.g., ARID1A, SMARCB1) are frequently mutated in cancer, altering the accessibility of genes
  4. Noncoding RNAs: miRNAs and lncRNAs regulate gene expression post-transcriptionally; e.g., miR-21 is overexpressed in many cancers and silences tumor suppressor targets; lncRNA HOTAIR promotes metastasis

XI. MULTISTEP CARCINOGENESIS

All cancers require sequential accumulation of multiple mutations - the concept of multistep carcinogenesis. Evidence comes from:
  • Epidemiologic data: Cancer incidence increases exponentially with age (time for mutation accumulation)
  • Experimental models: Normal human cells require at least 5 cooperating changes to become fully malignant (RAS activation + RB inactivation + p53 inactivation + PP2A inactivation + telomerase expression)
  • Colorectal adenoma-carcinoma sequence (the best-characterized example):
    • Normal epithelium → early adenoma: APC mutation (early gate-keeper)
    • Adenoma growth: KRAS mutation (proliferative advantage)
    • High-grade dysplasia: SMAD4, TGF-βRII loss
    • Carcinoma: TP53 mutation (late event)
    • Metastasis: Additional acquired alterations
Mutations in driver genes confer a growth advantage and are positively selected; passenger mutations accumulate but confer no selective advantage.

SUMMARY TABLE: Key Molecular Alterations in Cancer

HallmarkKey Genes/PathwaysMechanism
Growth self-sufficiencyRAS, EGFR, ERBB2, MYCOncogene activation - point mutation, amplification, translocation
Growth inhibition insensitivityRB, TP53, CDKN2A, APC, PTENTumor suppressor loss - deletion, mutation, methylation
Metabolic reprogrammingPI3K/AKT/mTOR, MYC, IDH1/2Warburg effect; oncometabolite production
Apoptosis evasionBCL-2, TP53, PI3K/AKTBCL-2 overexpression; TP53 loss; IAP upregulation
Replicative immortalityTERT (telomerase)Telomerase reactivation; escape from senescence
AngiogenesisVEGF, HIF-1α, bFGFHypoxia-driven; p53 loss; RAS/MYC activation
Invasion/MetastasisE-cadherin, MMPs, EMT TFsEMT; basement membrane degradation; organ tropism
Immune evasionPD-L1, MHC-I, TGF-βCheckpoint upregulation; antigen loss; immunosuppressive niche
Genomic instabilityTP53, MMR genes, BRCA1/2Defective DNA damage response and repair

CONCLUSION

Carcinogenesis is a multistep process driven by the accumulation of genetic and epigenetic alterations that confer the hallmarks of cancer upon cells. Oncogenes and tumor suppressor genes are the twin pillars of cancer genetics: oncogenes act in a dominant gain-of-function manner, while tumor suppressors act recessively requiring biallelic inactivation. Genomic instability acts as an enabling characteristic by accelerating mutation accumulation. Understanding these molecular mechanisms has directly translated into targeted therapies (BCR-ABL inhibitors, EGFR inhibitors, HER2-directed therapy, VEGF inhibitors, CDK4/6 inhibitors, PARP inhibitors, checkpoint inhibitors) that have transformed the management of multiple cancers.
Reference: Robbins & Cotran Pathologic Basis of Disease, 10th Edition, Chapter 7 - Neoplasia
This is a shared conversation. Sign in to Orris to start your own chat.